Categories
Change Password!
Reset Password!
Semaglutide provides effective heart protection in type 2 diabetes, cutting rates of serious cardiovascular events and coronary procedures.
Cardiovascular (CV) complications remain the key cause of morbidity and mortality in people suffering from type 2 diabetes mellitus (T2DM), despite advances in pharmacologic therapy. Glucagon-like peptide-1 receptor agonists (GLP-1RA), particularly semaglutide, are increasingly recognized for their potential to improve CV outcomes through multifaceted metabolic and anti-inflammatory mechanisms. Investigators aimed to evaluate the efficacy and safety of semaglutide in reducing CV events and related complications among adults with T2DM.
A comprehensive systematic review and meta-analysis was executed to examine semaglutide versus placebo in T2DM. A total of five trials involving 19,717 participants were included. The study evaluated a wide range of CV outcomes, including major adverse cardiovascular events (MACE), CV death, coronary revascularization, and cardiac-related complications, as well as all-cause mortality, heart failure (HF) hospitalizations, nonfatal heart attacks, stroke, unstable angina, and vascular disorders.
Effect sizes were calculated using rigorous meta-analytic methods, while study quality and bias risk were assessed through established evaluation criteria. As found, semaglutide was linked with a prominent decrease in MACE, CV death, the requisition for coronary revascularization, and cardiac disorder–linked adverse events. However, it did not show a statistically significant effect on all-cause mortality, hospitalization for HF, unstable angina, nonfatal myocardial infarction, stroke, or overall vascular disorders (Table 1).
Thus, semaglutide is more than a glucose-lowering agent—it is a cardioprotective therapy that improves CV outcomes in patients with T2DM, without compromising safety.
Cardiology in Review
Efficacy and Safety of Semaglutide on Cardiovascular Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Bacha Z et al.
Comments (0)